VFA cardiac resynchronization therapy

US11235159B2 · kind B2 · utility

Assignee

• Medtronic, Inc. · US

Inventors

• Zhongping Yang · Woodbury, US
• Thomas A. Anderson · New Hope, US
• Brian P. Colin · Anoka, US
• William J. Clemens · Fridley, US
• Subham Ghosh · Blaine, US
• Jeffrey M. Gillberg · Coon Rapids, US
• Maurice Verbeek · Borgharen, NL
• Toine Camps · Wittem, NL
• Lilian Kornet · Berg en Terblijt, NL
• Berthold Stegemann · Bonn, DE
• Jean Rutten · Liège, BE

Key dates

• Filing date: Mar 22, 2019
• Grant date: Feb 1, 2022
• Expiry date: Dec 18, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61N1/3756
• WIPO field: Medical technology
• WIPO sector: Instruments

Abstract

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue-piercing electrode implanted in the basal and/or septal region of the left ventricular myocardium of the patient's heart from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be implanted completely within the patient's heart or may use one or more leads to implant electrodes in the patient's heart. The device may be used to provide cardiac therapy, including single or multiple chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. A separate medical device may be used to provide some functionality for cardiac therapy, such as sensing, pacing, or shock therapy.